Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group

BACKGROUND: Pazopanib is a tyrosine kinase inhibitor with antiangiogenic activity. Vascular endothelial growth factor expression is increased in SCLC and is correlated with poor prognosis. The efficacy and tolerance of second-line pazopanib in SCLC was evaluated. PATIENTS AND METHODS: Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Koinis, F, Agelaki, S, Karavassilis, V, Kentepozidis, N, Samantas, E, Peroukidis, S, Katsaounis, P, Hartabilas, E, Varthalitis, I I, Messaritakis, I, Fountzilas, G, Georgoulias, V, Kotsakis, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520202/
https://www.ncbi.nlm.nih.gov/pubmed/28510571
http://dx.doi.org/10.1038/bjc.2017.137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520202/
https://www.ncbi.nlm.nih.gov/pubmed/28510571
http://dx.doi.org/10.1038/bjc.2017.137

Ejemplares similares